Oramed Pharmaceuticals (NASDAQ: ORMP) has developed an innovative technology to transform injectable treatments into oral therapies.
Oramed’s flagship product, an oral insulin capsule, has the potential to better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles.
Oramed’s oral insulin is currently in advanced clinical trials for type 2 diabetes.
To contact Kaleidoscope Data Privacy Consultants SL (KDPC SL), the EEA representative of Oramed Pharmaceuticals, please email their dedicated inbox at eea.oramed@kdpc.es
If you have a question about how your personal data is processed, please select your preferred language from the menu on the left.
You will find details on how to contact Kaleidoscope Data Privacy Consultants Limited (KDPC ES) including a form to request a telephone call or submit your question online.
More information about Oramed’s data protection policies can be found by on their website.
Kaleidoscope Data Privacy Consultants SL (KDPC ES) is the EEA Representative for the purposes of the General Data Protection Regulation (GDPR) for Oramed Pharmaceuticals, Inc through our office in Barcelona.
If you have a a question about how your personal data is processed, please select your preferred language from the menu on the left. Here you will find details on how to contact Kaleidoscope Data Privacy Consultants including a form to request a telephone call or submit your question online.
Contact details for our office in Spain:
Kaleidoscope Data Privacy Consultants SL, Calle Balmes 173, 4-2, Barcelona 08006, España
+34 (0) 938 004910 (Note: calls are answered in English. If you are not comfortable with English, please fill out the contact form and we will call you and speak in the language of your choice through an interpreter.)
Email: hello@kdpc.es
Web: www.kdpc.es